Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07659795 | 2 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | KRAS G12D -- targeted inhibitor (small molecule) |
| NCT07715903 | 1 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| NCT06557733 | 2 | TPST-1495 in Patients With Familial Adenomatous Polyposis | EP2/EP4 receptors -- antagonist (TPST-1495) |
| NCT07897721 | 1 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | PI3K alpha -- selective inhibitor (small molecule) |
| NCT07947134 | 1, 2 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 72 |
| Sun Yat-sen University | 53 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 27 |
| National Cancer Institute (NCI) | 15 |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | 14 |
Countries/regions with the most active trial sites for colorectal cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| May 6, 2027 | NCT07842965 | CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial | CCR5 -- monoclonal antibody (immune checkpoint inhibitor) |
| Dec 1, 2026 | NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | PD-1 + unknown target (ADG126) -- immune checkpoint blockade + unknown mechanism |
| Dec 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Dec 2026 | NCT07900165 | Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer | Topoisomerase I -- inhibitor (small molecule) |
| Nov 30, 2026 | NCT07859085 | A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma | KRAS G12D -- covalent inhibitor |
| Nov 24, 2026 | NCT07829588 | Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer | EGFR -- monoclonal antibody (anti-EGFR antibody) |
| Nov 23, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| Nov 15, 2026 | NCT07912463 | Phase Ib/II Trial of Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer | Serine/Glycine metabolism -- dietary restriction to modulate tumor metabolism (dietary intervention) |
You've seen the colorectal cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.